| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 514212070 |
Bicyclo ring system having the seven-membered hetero ring as one of the cyclos
| 89 |
| 514212060 |
Plural ring hetero atoms in the polycyclo ring system
| 54 |
| 514212050 |
Plural cyclos of the polycyclo ring system share ring nitrogen of the seven-membered hetero ring | 5 |
| 20090012058 | Prophylactic or Therapeutic Agents For Allergic Ophthalmic Diseases or Allergic Nasal Diseases, Comprising Tricyclic Triazolobenzazepine Derivative - The present invention provides a pharmaceutical composition for use in the prophylaxis or treatment of allergic ophthalmic diseases or allergic nasal diseases, which comprises 7,8-dimethoxy-4(5H),10-dioxo-1H-1,2,3-triazolo[4,5-c][1]benzazepine, 2-(1-isopropoxycarbonyloxy-2-methylpropyl)-7,8-dimethoxy-4(5H),10-dioxo-2H-1,2,3-triazolo[4,5-c][1]benzazepine or a pharmaceutically acceptable salt thereof. The pharmaceutical composition according to the present invention has few side effects, exerts strong prophylactic and therapeutic effects in the late phase exhibiting pharmaceutical resistance to conventional instillations, and can be used appropriately for topical applications. | 01-08-2009 |
| 20090181945 | TWO CYCLIC CINNAMIDE COMPOUND - The present invention relates to a novel two cyclic cinnamide compound and a pharmaceutical agent comprising the compound as an active ingredient. The two cyclic cinnamide compound represented by the general formula (I): | 07-16-2009 |
| 20100267692 | SMAC MIMETIC COMPOUNDS AS APOPTOSIS INDUCERS - The present invention relates to compounds conformationally constrained mimetics of Smac with function as inhibitors of Inhibitor of Apoptosis Proteins (IAPs), the invention also relates to the use of these compounds in therapy, wherein the induction of apoptotic cell death is beneficial, especially in the treatment of cancer, alone or in combination with other active ingredients. | 10-21-2010 |
| 20110281845 | ORGANIC COMPOUNDS - The present disclosure relates to XIAP inhibitor compounds of the formula I. | 11-17-2011 |
| 20130317007 | ANTIOXIDANT INFLAMMATION MODULATORS: OLEANOLIC ACID DERIVATIVES WITH AMINO AND OTHER MODIFICATIONS AT C-17 - This invention provides, but is not limited to, novel oleanolic acid derivatives having the formula: | 11-28-2013 |
| Entries |
| Document | Title | Date |
|---|
| 20080214522 | Antiviral indoles - Compounds of the formula (I): | 09-04-2008 |
| 20080275024 | CYCLIC MALONAMIDES AS INHIBITORS OF ASS PROTEIN PRODUCTION - This invention relates to novel cyclic malonamides having the formula (I): | 11-06-2008 |
| 20080312210 | USE OF A SPECIFIC CYCLIC AMINE DERIVATIVE OR THE PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF FOR THE TREATMENT OR PREVENTION OF HEART FAILURE - The present invention provides the use in a pharmaceutical composition of a specific cyclic amine derivative, or its pharmaceutically acceptable salts, for the treatment of heart failure of any aetiology. | 12-18-2008 |
| 20090069293 | SUCCINOYLAMINO BENZODIAZEPINES AS INHIBITORS OF AB PROTEIN PRODUCTION - This invention relates to novel lactams having the formula (I): | 03-12-2009 |
| 20090111793 | HYDROXYALKANOYLAMINOLACTAMS AND RELATED STRUCTURES AS INHIBITORS OF A BETA PROTEIN PRODUCTION - This invention relates to novel lactams having the formula (I): | 04-30-2009 |
| 20090192140 | IAP BIR DOMAIN BINDING COMPOUNDS - Disclosed herein is an isomer, enantiomer, diastereoisomer or tautomer of a compound represented by Formula I: | 07-30-2009 |
| 20100041639 | CYCLIC MALONAMIDES AS INHIBITORS OF A BETA PROTEIN PRODUCTION - This invention relates to novel cyclic malonamides having the formula (I): | 02-18-2010 |
| 20100069359 | CONSTRAINED SPIROCYCLIC COMPOUNDS AS CGRP RECEPTOR ANTAGONISTS - Compounds of formula I: | 03-18-2010 |
| 20100216772 | Novel Phenantridine Analogues and Uses Thereof - The present invention relates to compounds of the general formula (IV) and (II) and salts and physiologically functional derivatives thereof, | 08-26-2010 |
| 20110178065 | NOVEL CYP17 INHIBITORS - Provided herein are inhibitors of CYP17 enzyme. Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of a compound or pharmaceutical composition described herein to treat androgen-dependent diseases, disorders and conditions. | 07-21-2011 |
| 20110245233 | ANTIOXIDANT INFLAMMATION MODULATORS: OLEANOLIC ACID DERIVATIVES WITH SATURATION IN THE C-RING - This invention provides, but is not limited to, novel oleanolic acid derivatives having the formula: | 10-06-2011 |
| 20120184529 | COMBINATION THERAPY - The present invention relates to a combination therapy of 2-Chloro-N-(4-chloro-pyridin-2-yl-phenyl)-4-methanesulfonyl-benzamide and 2,2-Dimethyl-N-((S)-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl)-N′-(2,2,3,3,3-pentafluoro-propyl)-malonamide for treating a patient suffering from a proliferative disorder. | 07-19-2012 |
| 20120225860 | METHOD FOR ADMINISTRATION OF A GAMMA SECRETASE INHIBITOR - There are provided a new dosage regimens for the gamma secretase inhibitor 2,2-Dimethyl-N-((S)-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl)-N′-(2,2,3,3,3-pentafluoro-propyl)-malonamide which maximizes anti-tumor activity while maintaining acceptable toxicity levels. | 09-06-2012 |
| 20120238549 | Nuclear Hormone Receptor Modulators - The invention provides a compound of Formula (I) | 09-20-2012 |
| 20120295886 | ANTIVIRAL COMPOUNDS AND THEIR METHODS OF USE - The present disclosure provides compounds having affinity for the M2 proton channel, useful for the treatment of viral infections such as influenza, which are of the Formula (I): | 11-22-2012 |
| 20130196976 | COMPOSITIONS FOR REDUCING BETA-AMYLOID-INDUCED NEUROTOXICITY COMPRISING BETA-SECRETASE INHIBITOR - Disclosed are a composition for reducing beta amyloid-induced neurotoxicity by inhibiting β-secretase activity, comprising a dibenzofuran derivative, and a method for preparing the same. Further disclosed is that the combination of the dibenzofuran derivative with a γ-secretase inhibitor or an anti-inflammatory agent shows higher activity with respect to reducing beta amyloid-induced neurotoxicity. | 08-01-2013 |
| 20130217674 | SHIP1 MODULATORS AND RELATED METHODS - Compounds of structure (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R | 08-22-2013 |
| 20130281437 | METHOD FOR CANCER THERAPY - The present invention provides a method for treating a patient having cancer comprising administering to the patient a therapeutically effective amount of compound (1), or a pharmaceutically acceptable salt thereof, having the formula: | 10-24-2013 |
| 20140357620 | METHOD FOR ADMINISTRATION OF A GAMMA SECRETASE INHIBITOR - There are provided a new dosage regimens for the gamma secretase inhibitor 2,2-Dimethyl-N-((S)-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl)-N-(2,2,3,3,3-pentafluoro-propyl)-malonamide which maximizes anti-tumor activity while maintaining acceptable toxicity levels. | 12-04-2014 |
| 20150320734 | TREATMENT FOR CEREBRAL PALSY GAIT IMPAIRMENT - A methylphenidate, particularly including dextro-threo-methylphenidate, is administered to a child to treat a gait impairment secondary to cerebral palsy, or a gait impairment resultant side effect from anti-cancer and anti-seizure drugs. The administered methylphenidate simultaneously treats speech and gait or limb impairments secondary to a disease or disorder. | 11-12-2015 |
| 20150374647 | THERAPEUTIC APPROACHES FOR TREATING EPILEPSY AND RELATED DISORDERS THROUGH REDUCTION OF EPILEPTOGENESIS - The present invention relates to compositions and methods for the treatment of epilepsy and related disorders. More specifically, the present invention relates to novel combinatorial therapies of epilepsy and related disorders. | 12-31-2015 |
